Host-directed therapies for antimicrobial resistant respiratory tract infections.
Identifieur interne : 001072 ( PubMed/Checkpoint ); précédent : 001071; suivant : 001073Host-directed therapies for antimicrobial resistant respiratory tract infections.
Auteurs : Markus Maeurer [Royaume-Uni] ; Martin Rao ; Alimuddin ZumlaSource :
- Current opinion in pulmonary medicine [ 1531-6971 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- usage thérapeutique : Anti-infectieux.
- Humains, Infections de l'appareil respiratoire, Mucoviscidose, Résultat thérapeutique.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Anti-Infective Agents.
- therapy : Respiratory Tract Infections.
- Cystic Fibrosis, Humans, Treatment Outcome.
Abstract
Antimicrobial-resistant respiratory tract infections (AMR-RTIs) are increasing, presenting important management challenges worldwide. Current management of AMR-RTI patients focuses on pathogen-directed antimicrobial treatment. Overt lung inflammation, parenchymal damage, and ineffective immune activation perpetrate increased patient morbidity and mortality. Immunomodulatory and tissue-regenerative host-directed therapies (HDT) may improve treatment outcomes. HDTs under investigation for improving AMR-RTI treatment outcomes are reviewed.
DOI: 10.1097/MCP.0000000000000271
PubMed: 26989822
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26989822Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Host-directed therapies for antimicrobial resistant respiratory tract infections.</title><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation wicri:level="3"><nlm:affiliation>aDivision of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet bCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden cDivision of Infection and Immunity, University College London dNIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>aDivision of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet bCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden cDivision of Infection and Immunity, University College London dNIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26989822</idno><idno type="pmid">26989822</idno><idno type="doi">10.1097/MCP.0000000000000271</idno><idno type="wicri:Area/PubMed/Corpus">001203</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001203</idno><idno type="wicri:Area/PubMed/Curation">001203</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001203</idno><idno type="wicri:Area/PubMed/Checkpoint">001072</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001072</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Host-directed therapies for antimicrobial resistant respiratory tract infections.</title><author><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name><affiliation wicri:level="3"><nlm:affiliation>aDivision of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet bCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden cDivision of Infection and Immunity, University College London dNIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>aDivision of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet bCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden cDivision of Infection and Immunity, University College London dNIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name></author></analytic><series><title level="j">Current opinion in pulmonary medicine</title><idno type="eISSN">1531-6971</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Infective Agents (therapeutic use)</term><term>Cystic Fibrosis</term><term>Humans</term><term>Respiratory Tract Infections (therapy)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anti-infectieux (usage thérapeutique)</term><term>Humains</term><term>Infections de l'appareil respiratoire ()</term><term>Mucoviscidose</term><term>Résultat thérapeutique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Respiratory Tract Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-infectieux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cystic Fibrosis</term><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Infections de l'appareil respiratoire</term><term>Mucoviscidose</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antimicrobial-resistant respiratory tract infections (AMR-RTIs) are increasing, presenting important management challenges worldwide. Current management of AMR-RTI patients focuses on pathogen-directed antimicrobial treatment. Overt lung inflammation, parenchymal damage, and ineffective immune activation perpetrate increased patient morbidity and mortality. Immunomodulatory and tissue-regenerative host-directed therapies (HDT) may improve treatment outcomes. HDTs under investigation for improving AMR-RTI treatment outcomes are reviewed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26989822</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-6971</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Current opinion in pulmonary medicine</Title><ISOAbbreviation>Curr Opin Pulm Med</ISOAbbreviation></Journal><ArticleTitle>Host-directed therapies for antimicrobial resistant respiratory tract infections.</ArticleTitle><Pagination><MedlinePgn>203-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MCP.0000000000000271</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Antimicrobial-resistant respiratory tract infections (AMR-RTIs) are increasing, presenting important management challenges worldwide. Current management of AMR-RTI patients focuses on pathogen-directed antimicrobial treatment. Overt lung inflammation, parenchymal damage, and ineffective immune activation perpetrate increased patient morbidity and mortality. Immunomodulatory and tissue-regenerative host-directed therapies (HDT) may improve treatment outcomes. HDTs under investigation for improving AMR-RTI treatment outcomes are reviewed.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Various HDTs are being developed or evaluated for adjunctive AMR-RTI treatment. α-1 antitrypsin was shown to reduce Pseudomonas aeruginosa burden in the airways of cystic fibrosis patients. Cellular therapy by reinfusing autologous bone marrow-derived MSCs into MDR/XDR-TB patients shows promise, whereas adjunctive T cell-based therapies are considered. Cytotoxic therapy using etoposide, a topoisomerase II-inhibiting anticancer drug extends survival of patients with severe influenza H1N1 infection-induced hemophagocytic lymphohistiocytosis. Two other novel HDT candidates, DAS181 and resveratrol show antiinfluenza effects. Novel kinase inhibitors SB203580 (MAPK-2 antagonist) and LY294002 (phosphoinositide-3 kinases antagonist) exhibit promising anti-MERS-CoV activity. Palivizumab, an anti-RSV monoclonal antibody, effectively prevents RSV infection in high-risk paediatric populations. T-cell therapy is currently considered for adjunctive HDT of azole-resistant pulmonary aspergillosis.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Novel HDTs may revolutionize future treatment regimens for AMR-RTIs. Well designed multisite clinical trials are now necessary to accelerate progress.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maeurer</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>aDivision of Therapeutic Immunology (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet bCentre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden cDivision of Infection and Immunity, University College London dNIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zumla</LastName><ForeName>Alimuddin</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Pulm Med</MedlineTA><NlmUniqueID>9503765</NlmUniqueID><ISSNLinking>1070-5287</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003550" MajorTopicYN="N">Cystic Fibrosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26989822</ArticleId><ArticleId IdType="doi">10.1097/MCP.0000000000000271</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><noCountry><name sortKey="Rao, Martin" sort="Rao, Martin" uniqKey="Rao M" first="Martin" last="Rao">Martin Rao</name><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Maeurer, Markus" sort="Maeurer, Markus" uniqKey="Maeurer M" first="Markus" last="Maeurer">Markus Maeurer</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001072 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001072 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26989822
|texte= Host-directed therapies for antimicrobial resistant respiratory tract infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26989822" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |